title: ALT CHANGES AND ADVERSE EVENTS OF TELBIVUDINE IN HEPATITIS-B PATIENTS-AN EXPERIENCE OF 11 PATIENTS.
abstract: Hepatitis-B virus (HBV) infection is a major global health problem. Of the two billion people who have been infected, more than 350 million have chronic hepatitis. It is estimated that 235,000-328,000 people die annually due to liver cirrhosis and hepatocellular carcinoma, we assessed the short term outcomes of treatment with telbivudine in 11 adults aged 14-41 years with HBeAg-positive or HBeAg-negative chronic hepatitis-B (CHB). Treatment of chronic hepatitis-B patients with telbivudine shows 43.1% reduction in serum ALT with no significant adverse effects.
authors.forename: Zeeshan
authors.initials: Z
authors.lastname: Ali
authors.forename: Neeta
authors.initials: N
authors.lastname: Maheshwary
authors.forename: Uffaq
authors.initials: U
authors.lastname: Zara
authors.forename: Siddiqi
authors.initials: S
authors.lastname: Ahson
authors.forename: Muhammad Athar
authors.initials: MA
authors.lastname: Khan
mesh_terms: D000293:Adolescent; D000328:Adult; D000410:Alanine Transaminase / Q000097:blood*; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D005260:Female; D019694:Hepatitis B, Chronic / Q000188:drug therapy / Q000201:enzymology*; D006801:Humans; D008297:Male; D000077712:Telbivudine; D013936:Thymidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D015415:Biomarkers; D000077712:Telbivudine; D000410:Alanine Transaminase; D013936:Thymidine